<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESZOPICLONE</span><br/>(es-zo'pi-clone)<br/><span class="topboxtradename">Lunesta<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">anxiolytic</span><br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg, 3 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Eszopiclone is a nonbenzodiazepine sedative-hypnotic agent. The precise mechanism of action is unknown but believed to result
         from its interaction with GABA-receptor complexes at binding sites close to or coupled to benzodiazepine receptors in the
         brain. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improves sleep maintenance in transient insomnia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of insomnia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to eszopiclone; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment; elderly or debilitated patients; concurrent administration of <small>CNS DEPRESSANTS</small>; signs and symptoms of depression; pregnancy (category C). 
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 23 mg h.s.<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 12 mg h.s.<br/><br/><span class="indicationtitle">Severe Hepatic Impairment</span><br/><span class="rdroute">PO</span> <img src="../images/special/lesserorequal.gif"/>2 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>	Give immediately prior to bedtime.</li>
<li>	Store at 15°30° C (59° 86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Anxiety, confusion, depression, dizziness, hallucinations, <span class="speceff-common">headache,</span> irritability, decreased libido, nervousness, <span class="speceff-common">somnolence</span>. <span class="typehead">CV:</span>
<span class="speceff-common">Tachycardia,</span> pericardial infusion, left ventricular systolic dysfunction (LVSD). <span class="typehead">GI:</span> Dry mouth, dyspepsia, nausea, vomiting. <span class="typehead">GU:</span> Dysmenorrhea, gynecomastia. <span class="typehead">Respiratory:</span> Infection. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Unpleasant taste</span>.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Inhibitors of CYP3A4, including (but not limited to) <b>amiodarone,</b>
<span class="classification">antiretroviral protease inhibitors</span>
<b>,</b>
<b>aprepitant,</b>
<b>clarithromycin,</b>
<b>dalfopristin/quinupristin,</b>
<b>delavirdine,</b>
<b>diltiazem,</b>
<b>efavirenz </b>(inducer or inhibitor), <b>erythromycin,</b>
<b>fluconazole,</b>
<b>fluoxetine,</b>
<b>fluvoxamine,</b>
<b>itraconazole,</b>
<b>ketoconazole,</b>
<b>mifepristone,</b>
<b>nefazodone,</b>
<b>norfloxacin,</b> other systemic <span class="classification">azole antifungals</span> (<b>miconazole</b> and <b>voriconazole</b>), <b>troleandomycin,</b> and <b>zafirlukast </b>increase eszopiclone levels. <b>Ethanol</b> and other <span class="classification">cns depressant</span> agents can produce additive effects in combination with eszopiclone.  <span class="typehead">Herbal:</span>
<b>St. John's wort</b> can increase eszopiclone levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract.  <span class="typehead">Distribution:</span> 5259% protein bound. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Metabolism:</span> Extensive hepatic metabolism. <span class="typehead">Elimination:</span> Primarily eliminated in the urine. <span class="typehead">Half-Life:</span> 56 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>	Monitor for and report worsening insomnia and cognitive or behavioral changes.</li>
<li>	Monitor for S&amp;S of CNS depression when other <small>CNS DEPRESSANTS</small> are used concurrently.
         </li>
<li>	Supervise ambulation if patient is out of bed after taking eszopiclone.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Follow directions for taking the drug (see Administration).</li>
<li>	Do not take this drug unless you can get at least 8 h of sleep.</li>
<li>	Do not consume alcohol while taking this drug.</li>
<li>	Do not take with or immediately after a high fat meal.</li>
<li>	Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>	Report any of the following to a health care provider: worsening insomnia, cognitive or behavioral changes, problem with
            reproductive function.
         </li>
<li>	Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>